Albertsons Companies, Inc.

Albertsons Companies, Inc. (ACI) Market Cap

Albertsons Companies, Inc. has a market capitalization of $8.58B.

Financials based on reported quarter end 2025-11-29

Price: $16.70

0.33 (2.02%)

Market Cap: 8.58B

NYSE · time unavailable

CEO: Susan D. Morris

Sector: Consumer Defensive

Industry: Grocery Stores

IPO Date: 2020-06-26

Website: https://www.albertsonscompanies.com

Albertsons Companies, Inc. (ACI) - Company Information

Market Cap: 8.58B · Sector: Consumer Defensive

Albertsons Companies, Inc., through its subsidiaries, engages in the operation of food and drug stores in the United States. The company's food and drug retail stores offer grocery products, general merchandise, health and beauty care products, pharmacy, fuel, and other items and services. It also manufactures and processes food products for sale in stores. As of February 26, 2022, it operated 2,276 stores under various banners, including Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, Acme, Shaw's, Star Market, United Supermarkets, Market Street, Haggen, Kings Food Markets, and Balducci's Food Lovers Market; and 1,722 pharmacies, 1,317 in-store branded coffee shops, 402 adjacent fuel centers, 22 distribution centers, and 20 manufacturing facilities, as well as various digital platforms. The company was founded in 1860 and is headquartered in Boise, Idaho.

Analyst Sentiment

67%
Buy

Based on 21 ratings

Analyst 1Y Forecast: $22.57

Average target (based on 4 sources)

Consensus Price Target

Low

$14

Median

$20

High

$29

Average

$20

Potential Upside: 22.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALBERTSONS COMPANY INC CLASS A (ACI) — Investment Overview

🧩 Business Model Overview

Albertsons Companies Inc (NYSE: ACI) is one of the largest food and drug retailers in the United States, operating a network of supermarkets, drug stores, and related retail outlets. The company serves millions of customers across multiple banners, including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, and others. Albertsons deploys a multi-format strategy encompassing neighborhood supermarkets, stand-alone pharmacies, and e-commerce platforms, catering to a broad spectrum of demographics and income segments. The company’s core operations focus on the sale of food, groceries, pharmacy items, fuel, general merchandise, and health/wellness products. Albertsons balances its physical store base with ongoing investment in digital transformation and omnichannel capabilities, adapting to a dynamic retail environment. Through targeted store renovations, private label expansion, and a granular localization strategy, Albertsons aims to differentiate itself in a crowded and competitive sector.

💰 Revenue Streams & Monetisation Model

Albertsons generates revenues predominantly from in-store food and grocery sales, accounting for the lion’s share of its topline. Key revenue categories include fresh produce, meat, dairy, bakery, and center store packaged goods. The company supplements these core sales with pharmacy prescriptions, over-the-counter drugs, and health/wellness products available both in-store and via digital platforms. Additional monetization streams come from private label brands, which Albertsons has methodically expanded to capture higher margins and foster customer loyalty. The company also participates in fuel retailing at select locations, driving incremental traffic and cross-category spending. Its digital and e-commerce segment—the fastest growing channel—encompasses online grocery pickup and delivery, enhanced through partnerships and internal fulfillment solutions. Albertsons further monetizes through ancillary services such as in-store financial services, gift cards, loyalty programs, and advertising relationships with CPG brands seeking premium shelf and promotional placement within its expansive network.

🧠 Competitive Advantages & Market Positioning

Albertsons’ scale and national footprint provide substantial bargaining power with suppliers and access to a large, diversified customer base. The company’s regional banner strategy allows for a hyperlocal approach while benefiting from centralized procurement, operational efficiencies, and technology investments. This blended model fosters brand affinity in each local market, responsive category management, and swift adaptation to changing consumer preferences. Private label penetration is a distinct competitive lever, enabling Albertsons to protect margins, control product quality, and cultivate loyalty in an environment increasingly disrupted by discount retailers and alternative formats. The integration of pharmacy operations further drives recurring traffic, deepening customer engagement and underpinning a robust data analytics infrastructure for personalized marketing. Omnichannel development—including curbside pickup, home delivery, and mobile app engagement—is a core differentiator, meeting evolving consumer expectations for convenience and flexibility. The company’s loyalty program and digital personalization initiatives further reinforce repeat business and wallet share. In the broader context, Albertsons is positioned as a top-tier player in a structurally defensive, essential goods sector, with resilience across business cycles.

🚀 Multi-Year Growth Drivers

Several secular tailwinds and executional levers underpin Albertsons’ long-term growth prospects: - **Omnichannel Acceleration:** Continued expansion of digital capabilities—integrated e-commerce, app-based shopping, curbside pickup, and delivery services—drive higher average spend and customer retention rates. - **Private Label Expansion:** Accelerated penetration and innovation within high-margin private labels broaden customer selection while reinforcing margin stability. - **Store Refresh & Optimization:** Strategic capital allocation to remodel, relocate, or upgrade stores optimize productivity and keep the physical portfolio relevant. - **Pharmacy & Health Services Growth:** Growing importance of healthcare and in-store pharmacy services, including immunizations and clinical offerings, expand the addressable market. - **Personalization & Loyalty Analytics:** Data-driven marketing programs foster greater frequency and depth of spend among core and fringe customers. - **Supply Chain & Efficiency Initiatives:** Investments in technology and automation drive cost efficiencies, improve inventory turns, and mitigate inflationary pressures.

⚠ Risk Factors to Monitor

- **Competitive Intensity:** The grocery space remains structurally competitive, with pricing pressure from traditional grocers, big box discounters, dollar stores, club formats, and e-commerce entrants. - **Margin Pressures:** Supply chain inflation, rising labor costs, and fluctuating commodity prices can compress operating margins, especially in a low-margin sector. - **Digital Disruption:** Rapid consumer adoption of digital grocery platforms poses disintermediation risk, necessitating constant investment and innovation to stay relevant. - **Operational Execution:** Complex multi-banner integration and modernization require disciplined project management and can expose the company to transition risks or inefficiencies. - **Regulatory & Healthcare Shifts:** As a significant pharmacy operator, Albertsons faces changing healthcare regulations, reimbursement rates, and potential legal liabilities. - **Leverage & Balance Sheet Considerations:** Debt levels and lease obligations may constrain financial flexibility in navigating macroeconomic or sector-specific volatility.

📊 Valuation & Market View

Albertsons is often valued at a discount to pure-play e-commerce and high-growth peers, reflecting the mature, cash-generative, but low-margin nature of grocery retailing. Standard valuation multiples—such as EV/EBITDA, forward P/E, and price-to-cash flow—typically benchmark below secular growth retailers, yet above structurally challenged regional grocers. Investors weigh ACI's consistent free cash flow generation, dividend potential, and capital return track record against the persistence of competitive dynamics and underlying structural risks. Market sentiment generally appreciates Albertsons’ defensive business qualities, resilient demand profile, and ongoing transformation efforts. The possibility of further consolidation, strategic partnerships, or real estate monetization introduces optionality into the long-term investment case. However, sustained outperformance is expected only if the company can maintain or grow traffic in a deflationary pricing environment while efficiently balancing in-store and online execution.

🔍 Investment Takeaway

Albertsons Companies Inc stands as a leading, operationally sophisticated grocery and pharmacy retailer with national reach and entrenched local presence. Its multi-pronged growth strategy—anchored by omnichannel innovation, private label expansion, and healthcare relevance—positions the company to navigate industry shifts and capitalize on evolving consumer behaviors. While the sector’s structurally narrow margins and competitive threats call for vigilant execution and cost management, Albertsons offers investors exposure to a resilient, essential goods category with strong free cash flow characteristics. The company’s ongoing digital transformation and balance sheet discipline provide additional levers for value creation. Prospective investors should weigh the company’s stable cash flows and defensive positioning against executional and structural risks inherent to the retail grocery space.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-11-29

"Albertsons Companies Inc. reported quarterly revenue of $19.12 billion with a net income of $293 million. Earnings per share stood at $0.55, resulting in a net margin of approximately 1.53%. The company produced an impressive free cash flow of $1.19 billion, highlighting robust operational efficiency. Year-over-year growth remains modest; however, net income shows stability. Operating cash flow demonstrates strong cash generation, and capital expenditures are strategically maintained to support future growth. With total assets of $27.09 billion and liabilities at $24.59 billion, the equity stands at $2.50 billion. The net debt of $15.24 billion indicates a leveraged balance sheet, but ongoing debt repayments are noteworthy. Shareholder returns include $77.1 million paid in dividends and significant stock buybacks totaling $649.6 million, reflecting management's commitment to returning capital to shareholders. Analyst price targets up to $29 suggest potential upside based on current valuations. Overall, Albertsons presents a solid financial position with notable cash flow generation, although attention to debt levels is advisable for long-term stability."

Revenue Growth

Neutral

Revenue growth is stable but not rapid, driven by core operations. Given the scale, growth is consistent but moderate.

Profitability

Positive

Profit margins remain modest with a steady EPS trend suggesting operational efficiency. Net margin stands at 1.53%.

Cash Flow Quality

Good

Strong free cash flow generation indicates efficient operations. Liquidity is supported by positive operating cash flow.

Leverage & Balance Sheet

Fair

While net debt is high, reflecting a leveraged position, continuous debt repayments enhance financial resilience.

Shareholder Returns

Neutral

The stock has appreciated moderately over the year, and capital returns include dividends and significant buybacks.

Analyst Sentiment & Valuation

Positive

Valuation appears reasonable with analyst targets suggesting upside potential. Ratios indicate fair valuation contextually.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

ACI delivered resilient profitability in Q4 despite sharper-than-expected pharmacy-driven top-line pressure. Identical sales rose 0.7% but included ~145 bps net pharmacy headwinds versus the prior Q3 outlook (IRA pricing/mix ~105 bps and a further ~40 bps from GLP-1 growth moderation). Margin was partially protected because generics are structurally accretive, though gross margin still fell 25 bps YoY (27.2% excluding fuel/LIFO) largely from digital mix and reduced sales volume effects. Management emphasized operating leverage from a scaled productivity engine: FY25 showcased funding capacity for investment while generating adjusted EBITDA of $903M (including 53rd week). For 2026, guidance calls for adjusted EBITDA $3.85B–$3.925B and adjusted EPS $2.22–$2.32, alongside ~$600M share repurchases and capex $2.0B–$2.2B. The key near-term risk is ongoing IRA headwinds (~150 bps to reported identical sales) plus Q1 egg deflation effects; however, management expects sequential improvement into the back half supported by AI-enabled merchandising/labor/supply chain tools and loyalty/digital scale (including 90% lift in retail media pilot performance).

AI IconGrowth Catalysts

  • Digital penetration surpassed 10% in Q4; first-party digital contributed nearly 90% of 16% digital growth
  • AI-enabled shopping assistance driving meaningful lift in basket size and personalization (conversion/basket/loyalty)
  • Retail media: personalized ad pilots delivered 90% lift in conversion and click-through rates
  • Pharmacy customer lifetime value improvement from grocery+pharmacy engagement (pharmacy profitability improvement despite top-line pressure)
  • Food now / meal solutions: deli & prepared foods drive >1/3 of total trips; outsized share of wallet continuing to grow
  • Loyalty flywheel: membership grew 12% to >51 million; more redemption via cash-off option

Business Development

  • Retail media merchant partnerships (embedded into customer journey; “merchant partnerships” referenced; no named external partners/counterparties in transcript)
  • Opioid legal settlement framework: $774 million proposed nationwide opioid settlement payable over 9 years (legal framework, not a commercial partnership)
  • Gateway proprietary AI-powered tool for inventory efficiency and replenishment for promotional center store SKUs (internal product/tool)

AI IconFinancial Highlights

  • Identical sales +0.7% in Q4; net of ~145 bps pharmacy-related headwinds vs prior Q3 outlook of ~65–70 bps
  • Pharmacy headwind composition: ~105 bps from IRA pricing/mix pressure and generic-to-brand mix shift; additional ~40 bps from moderation in GLP-1 growth (tighter payer criteria + increased direct-to-consumer penetration)
  • ID sales margin impact favorable (generics structurally more accretive) offsetting top-line pressure
  • Gross margin: 27.2% in Q4, down 25 bps YoY excluding fuel and LIFO; mix shift from outsized growth in digital sales partially offset by productivity and surgical price investments
  • SG&A expense (ex fuel + opioid settlement framework): improved 2 bps YoY; SG&A rate unfavorable due to lower sales from pharmacy IRA impact
  • Adjusted EBITDA: $903 million in Q4 (including ~$68 million from the 53rd week); “better-than-expected adjusted EBITDA flow-through”
  • Adjusted EPS: $0.48 per diluted share in Q4
  • Full year 2025: identical sales +2%; adjusted EBITDA $3.9 billion
  • Effective tax rate guidance 2026: 24%–25%
  • Pharmacy IRA assumed as ~150 bps headwind to reported identical sales guidance for 2026

AI IconCapital Funding

  • Returned >$1.8 billion to shareholders in FY25: $322 million dividends and nearly $1.5 billion share repurchases
  • Completed $750 million accelerated share repurchase program (ASR) in FY25
  • Quarterly dividend increased 13% to $0.68 per share (announced during call)
  • Refreshed/renewed share repurchase authorization to $2.0 billion total after ASR completion; expected completion over ~3 years
  • 2026 share repurchases expected: ~$600 million during fiscal 2026
  • Net debt / adjusted EBITDA: 2.24x at year-end (capacity to fund growth/returns)
  • Opportunistic debt refinancing in Q4: refinanced $2.1 billion in 2 tranches (5.625% notes due 2032: $1.2B; 5.75% tack-on notes due 2034: $0.9B) using proceeds to refinance $1.35B 2027 and $0.75B 2028 maturities
  • FY25 capital expenditures: $1.84 billion

AI IconStrategy & Ops

  • 4 “big bets”: digital customer experience, merchandising intelligence, labor optimization, supply chain optimization (long-term structural initiatives)
  • Automation/AI across merchandising stores and supply chain to improve efficiency; productivity funded rather than short-term trade-offs
  • Supply chain: AI demand forecasting + computer vision for availability/quality/freshness; launched “Gateway” AI tool for promotional center store SKUs
  • Labor optimization: generative AI scheduling tools to improve forecast accuracy and labor efficiency
  • Merchandising intelligence: automated insights + intelligent pricing tools to improve category decision-making and structurally stronger margins; tools to reimagine price/promotional strategy and assortment decisions
  • Productivity scaling: $2.0 billion 3-year productivity program (reset from prior $1.5B expectation; ratable over 3 years)
  • Q4 capex/store footprint: remodeled 94 stores and opened 9 stores in FY25
  • Store optimization framework for 2026+: banner optimization, store modernization, market densification, and store rationalization where economics are structurally challenged

AI IconMarket Outlook

  • 2026 identical sales guidance: range 0% to 1% OR 1.5% to 2.5% excluding the 150 bps IRA headwind and assuming near-flat reported pharmacy sales
  • Q1 2026 identical sales: expected to track below full-year range (including IRA and significant ongoing egg deflation); management expects sequential improvement after Q1 and “likely positive in the back half”
  • Adjusted EBITDA 2026 guidance: $3.85B to $3.925B (top end ~2.5% growth excluding 53rd week impact in 2025)
  • Adjusted EPS 2026 guidance: $2.22 to $2.32, including approx. $600M of share repurchases
  • Capital expenditures 2026 guidance: $2.0B to $2.2B
  • Food inflation expectation: ~2% range (industry), though management noted they have not been passing through at the full 2% rate

AI IconRisks & Headwinds

  • Pharmacy headwinds from Inflation Reduction Act: ~145 bps net headwind to Q4 ID sales expectations; ~105 bps from IRA pricing/mix pressure and generic-to-brand mix shift; ~40 bps from GLP-1 growth moderation (tighter payer criteria; increased direct-to-consumer penetration)
  • Reported identical sales pressured by grocery affordability/units weakness in lowest income cohorts
  • Deflation and cycling prior-year egg shortages: expected to persist into Q1 2026
  • Gross margin headwind: mix shift impact from outsized growth in digital sales (digital margins still below grocery) and down 25 bps YoY excluding fuel and LIFO in Q4
  • Lower sales impacts: SG&A rate unfavorable due to lower sales from pharmacy IRA
  • Potential incremental pressure if higher fuel costs persist (fuel/transportation/distribution costs included in outlook; incremental risk if not temporary)

Sentiment: MIXED

Note: This summary was synthesized by AI from the ACI Q4 2025 (conference date: 2026-04-14) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ACI)

© 2026 Stock Market Info — Albertsons Companies, Inc. (ACI) Financial Profile